Abivax SA Sponsored ADR $ABVX Position Boosted by Legato Capital Management LLC

Legato Capital Management LLC increased its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 316.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 10,648 shares of the company’s stock after purchasing an additional 8,094 shares during the quarter. Legato Capital Management LLC’s holdings in Abivax were worth $1,436,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its stake in Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares in the last quarter. WPG Advisers LLC boosted its stake in Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares in the last quarter. Union Bancaire Privee UBP SA bought a new position in Abivax during the 4th quarter valued at $67,000. Hantz Financial Services Inc. bought a new position in Abivax during the 3rd quarter valued at $52,000. Finally, Assetmark Inc. bought a new position in Abivax during the 4th quarter valued at $84,000. 47.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ABVX has been the subject of a number of research reports. Wedbush initiated coverage on Abivax in a research note on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price target for the company. Barclays increased their price target on Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Jefferies Financial Group assumed coverage on Abivax in a research note on Monday, March 16th. They set a “buy” rating and a $160.00 price target for the company. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Abivax has an average rating of “Moderate Buy” and an average target price of $137.15.

Abivax Stock Performance

Shares of NASDAQ:ABVX opened at $121.99 on Monday. Abivax SA Sponsored ADR has a one year low of $5.59 and a one year high of $148.83. The stock has a fifty day moving average of $117.74 and a 200-day moving average of $119.12. The company has a market capitalization of $9.72 billion, a PE ratio of -23.41 and a beta of 0.84.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts forecast that Abivax SA Sponsored ADR will post -3.84 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.